Skip To Main Content
Bourlon MT on Muck Rack

Bourlon MT

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Bourlon MT’s profile

Articles by Bourlon MT

Comments on “Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations (ARON‐1 study)”

|
By Molina-Cerrillo J, Bourlon MT, Wen-Jiang Yang, Horvat TZ
| Wiley Online Library Verified
No abstract is available for this article. REFERENCES 1, , , et al. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer. 2025; 1-10. doi:10.1002/ijc.70228 2, , , et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.
Open in Who Shared Issue with article?

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

|
By Myint ZW, De Giorgi U, Zucali PA, Bourlon MT
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (582) Issue with article?

Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database

|
By Bourlon MT, Kim SP, Kessler ER, Candelario NC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (634) Issue with article?

Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database

|
By Candelario NC, Bourlon MT, Kim SP, Kessler ER
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (626) Issue with article?

Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer

|
By Chávarri-Guerra Y, Bourlon MT, Rodríguez-Olivares JL, Rodríguez-Faure A
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (613) Issue with article?

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma - PubMed

|
By Geynisman DM, Bourlon MT, Barata PC, Blum SI
| nlm.nih.gov
Background: The comparative efficacy and health-related quality of life (HRQoL) outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not been assessed in head-to-head trials. Objective: To assess the efficacy and HRQoL outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib.
Open in Who Shared Issue with article?
Show More